Literature DB >> 16982743

Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.

Tanja Pejovic1, Jane E Yates, Hong Y Liu, Laura E Hays, Yassmine Akkari, Yumi Torimaru, Winifred Keeble, R Keaney Rathbun, William H Rodgers, Allen E Bale, Najim Ameziane, C Michael Zwaan, Abdellatif Errami, Philippe Thuillier, Fabio Cappuccini, Susan B Olson, Joanna M Cain, Grover C Bagby.   

Abstract

Fanconi anemia is an inherited cancer predisposition disease characterized by cytogenetic and cellular hypersensitivity to cross-linking agents. Seeking evidence of Fanconi anemia protein dysfunction in women at risk of ovarian cancer, we screened ovarian surface epithelial cells from 25 primary cultures established from 22 patients using cross-linker hypersensitivity assays. Samples were obtained from (a) women at high risk for ovarian cancer with histologically normal ovaries, (b) ovarian cancer patients, and (c) a control group with no family history of breast or ovarian cancer. In chromosomal breakage assays, all control cells were mitomycin C (MMC) resistant, but eight samples (five of the six high-risk and three of the eight ovarian cancer) were hypersensitive. Lymphocytes from all eight patients were MMC resistant. Only one of the eight patients had a BRCA1 germ-line mutation and none had BRCA2 mutations, but FANCD2 was reduced in five of the eight. Ectopic expression of normal FANCD2 cDNA increased FANCD2 protein and induced MMC resistance in both hypersensitive lines tested. No FANCD2 coding region or promoter mutations were found, and there was no genomic loss or promoter methylation in any Fanconi anemia genes. Therefore, in high-risk women with no BRCA1 or BRCA2 mutations, tissue-restricted hypersensitivity to cross-linking agents is a frequent finding, and chromosomal breakage responses to MMC may be a sensitive screening strategy because cytogenetic instability identified in this way antedates the onset of carcinoma. Inherited mutations that result in tissue-specific FANCD2 gene suppression may represent a cause of familial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982743     DOI: 10.1158/0008-5472.CAN-06-0222

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement.

Authors:  Jay W Wright; Tanja Pejovic; Leigh Jurevic; Cecily V Bishop; Theodore Hobbs; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

2.  Dynamics of the primate ovarian surface epithelium during the ovulatory menstrual cycle.

Authors:  Jay W Wright; Leigh Jurevic; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

3.  Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.

Authors:  Philip S Rudland; Angela M Platt-Higgins; Lowri M Davies; Suzete de Silva Rudland; James B Wilson; Abdulaziz Aladwani; John H R Winstanley; Dong L Barraclough; Roger Barraclough; Christopher R West; Nigel J Jones
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

4.  Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

Authors:  Richard D Kennedy; Clark C Chen; Patricia Stuckert; Elyse M Archila; Michelle A De la Vega; Lisa A Moreau; Akiko Shimamura; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

5.  Human FANCC is hypomorphic in murine Fancc-deficient cells.

Authors:  Laura E Hays; Winifred W Keeble; Jane E Yates; R K Rathbun; Tara Koretsky; Susan B Olson; Zejin Sun; D Wade Clapp; Grover C Bagby
Journal:  Blood       Date:  2010-06-16       Impact factor: 22.113

6.  Novel genetic variants in miR-191 gene and familial ovarian cancer.

Authors:  Jie Shen; Richard DiCioccio; Kunle Odunsi; Shashikant B Lele; Hua Zhao
Journal:  BMC Cancer       Date:  2010-02-18       Impact factor: 4.430

Review 7.  The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.

Authors:  Lindsey E Romick-Rosendale; Vivian W Y Lui; Jennifer R Grandis; Susanne I Wells
Journal:  Mutat Res       Date:  2013-01-17       Impact factor: 2.433

8.  TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells.

Authors:  Scott M Vanderwerf; Johanna Svahn; Susan Olson; R Keaney Rathbun; Christina Harrington; Jane Yates; Winifred Keeble; David C Anderson; Praveen Anur; Noemi F Pereira; Daniela V Pilonetto; Ricardo Pasquini; Grover C Bagby
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

9.  Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway.

Authors:  E E Hoskins; R W Gunawardena; K B Habash; T M Wise-Draper; M Jansen; E S Knudsen; S I Wells
Journal:  Oncogene       Date:  2008-04-28       Impact factor: 9.867

10.  Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model.

Authors:  Qing-Shuo Zhang; Matthew Deater; Ngoc Phan; Andrea Marcogliese; Angela Major; Eva C Guinan; Markus Grompe
Journal:  Pediatr Blood Cancer       Date:  2018-09-25       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.